[1] MARKUS R MEYER Hans H M. Metabolism of designer drugs of abuse: an updated review.[J]. Current drug metabolism, 2010, 11 5: 468-482. DOI:
10.2174/138920010791526042[2] ARIANE WOHLFARTH Sebastian D Wolfgang Weinmann. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum[J]. Analytical and Bioanalytical Chemistry, 2010, 396 7: 2403-2414. DOI:
10.1007/s00216-009-3394-4[3] RAIMONDO BRUNO . Emerging psychoactive substance use among regular ecstasy users in Australia[J]. Drug and alcohol dependence, 2012, 124 1: Pages 19-25. DOI:
10.1016/j.drugalcdep.2011.11.020[4] PABLO R MOYA. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.[J]. Journal of Pharmacology and Experimental Therapeutics, 2007, 321 3: 1054-1061. DOI:
10.1124/jpet.106.117507[5] FUMIKO NAGAI Kanako S H K Ryouichi Nonaka. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain[J]. European journal of pharmacology, 2007, 559 2: Pages 132-137. DOI:
10.1016/j.ejphar.2006.11.075